Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 30 studies | 29% ± 13% | |
pericyte | 27 studies | 30% ± 11% | |
fibroblast | 19 studies | 26% ± 7% | |
smooth muscle cell | 14 studies | 23% ± 9% | |
capillary endothelial cell | 13 studies | 24% ± 9% | |
adipocyte | 10 studies | 33% ± 9% | |
endothelial cell of artery | 9 studies | 23% ± 4% | |
vein endothelial cell | 9 studies | 22% ± 5% | |
endothelial cell of vascular tree | 7 studies | 26% ± 9% | |
endothelial cell of lymphatic vessel | 6 studies | 19% ± 4% | |
oligodendrocyte precursor cell | 5 studies | 33% ± 8% | |
connective tissue cell | 5 studies | 23% ± 7% | |
myofibroblast cell | 4 studies | 23% ± 5% | |
astrocyte | 4 studies | 26% ± 6% | |
glomerular endothelial cell | 3 studies | 38% ± 6% | |
oligodendrocyte | 3 studies | 25% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
adipose | 3 studies | 24% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 20022.17 | 258 / 258 | 100% | 47.69 | 230 / 230 |
prostate | 100% | 20589.76 | 244 / 245 | 100% | 42.23 | 501 / 502 |
thymus | 100% | 24983.51 | 652 / 653 | 99% | 54.57 | 597 / 605 |
kidney | 100% | 18503.40 | 89 / 89 | 98% | 53.71 | 881 / 901 |
breast | 100% | 35419.64 | 459 / 459 | 97% | 35.03 | 1088 / 1118 |
ovary | 100% | 28395.94 | 180 / 180 | 96% | 29.40 | 414 / 430 |
lung | 100% | 24678.59 | 576 / 578 | 93% | 24.06 | 1070 / 1155 |
liver | 97% | 11447.99 | 219 / 226 | 95% | 27.55 | 386 / 406 |
brain | 91% | 7781.28 | 2401 / 2642 | 99% | 42.83 | 699 / 705 |
skin | 89% | 10152.71 | 1611 / 1809 | 100% | 43.02 | 471 / 472 |
esophagus | 92% | 21009.13 | 1325 / 1445 | 94% | 22.32 | 172 / 183 |
stomach | 96% | 13788.94 | 345 / 359 | 85% | 20.68 | 244 / 286 |
intestine | 99% | 18066.16 | 955 / 966 | 81% | 15.34 | 428 / 527 |
uterus | 99% | 31584.96 | 169 / 170 | 80% | 18.46 | 367 / 459 |
bladder | 100% | 23192.57 | 21 / 21 | 76% | 12.97 | 385 / 504 |
pancreas | 77% | 5400.41 | 251 / 328 | 98% | 36.16 | 175 / 178 |
adipose | 100% | 41911.22 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 32605.25 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 48.44 | 80 / 80 |
spleen | 100% | 24575.58 | 241 / 241 | 0% | 0 | 0 / 0 |
heart | 100% | 16747.14 | 859 / 861 | 0% | 0 | 0 / 0 |
muscle | 95% | 11036.48 | 766 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 73% | 9.09 | 33 / 45 |
lymph node | 0% | 0 | 0 / 0 | 48% | 4.94 | 14 / 29 |
peripheral blood | 0% | 5.56 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019725 | Biological process | cellular homeostasis |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0035264 | Biological process | multicellular organism growth |
GO_0001822 | Biological process | kidney development |
GO_0035335 | Biological process | peptidyl-tyrosine dephosphorylation |
GO_0014850 | Biological process | response to muscle activity |
GO_0046627 | Biological process | negative regulation of insulin receptor signaling pathway |
GO_0048871 | Biological process | multicellular organismal-level homeostasis |
GO_0032963 | Biological process | collagen metabolic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0005925 | Cellular component | focal adhesion |
GO_0005737 | Cellular component | cytoplasm |
GO_0019900 | Molecular function | kinase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0008289 | Molecular function | lipid binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0004725 | Molecular function | protein tyrosine phosphatase activity |
Gene name | TNS2 |
Protein name | Tensin like C1 domain containing phosphatase (Tensin 2) Tensin 2 Tensin-2 (EC 3.1.3.48) (C1 domain-containing phosphatase and tensin homolog) (C1-TEN) (Tensin-like C1 domain-containing phosphatase) |
Synonyms | TENC1 KIAA1075 |
Description | FUNCTION: Tyrosine-protein phosphatase which regulates cell motility, proliferation and muscle-response to insulin . Phosphatase activity is mediated by binding to phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) via the SH2 domain . In muscles and under catabolic conditions, dephosphorylates IRS1 leading to its degradation and muscle atrophy . Negatively regulates PI3K-AKT pathway activation . Dephosphorylates nephrin NPHS1 in podocytes which regulates activity of the mTORC1 complex . Under normal glucose conditions, NPHS1 outcompetes IRS1 for binding to phosphatidylinositol 3-kinase (PI3K) which balances mTORC1 activity but high glucose conditions lead to up-regulation of TNS2, increased NPHS1 dephosphorylation and activation of mTORC1, contributing to podocyte hypertrophy and proteinuria . Required for correct podocyte morphology, podocyte-glomerular basement membrane interaction and integrity of the glomerular filtration barrier (By similarity). Enhances RHOA activation in the presence of DLC1 . Plays a role in promoting DLC1-dependent remodeling of the extracellular matrix . . |
Accessions | Q63HR2 F8VV64 ENST00000314276.7 [Q63HR2-4] ENST00000379902.7 [Q63HR2-5] ENST00000546602.5 [Q63HR2-2] ENST00000546772.1 A7E2A6 R4GMX1 ENST00000552570.5 [Q63HR2-6] ENST00000602335.1 ENST00000314250.11 [Q63HR2-1] ENST00000549700.5 H0YID7 |